Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Eliem Therapeutics, Inc. | elym-20210630ex32_2.htm |
| EX-31.2 - EX-31.2 - Eliem Therapeutics, Inc. | elym-20210630ex31_2.htm |
| EX-31.1 - EX-31.1 - Eliem Therapeutics, Inc. | elym-20210630ex31_1.htm |
| 10-Q - 10-Q - Eliem Therapeutics, Inc. | elym-20210630.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Eliem Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
Date: September 13, 2021 |
|
By: |
/s/ Robert Azelby |
|
|
|
Robert Azelby |
|
|
|
Chief Executive Officer |
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Eliem Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.